Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer

Summary

This phase II trial studies the effect of selpercatinib given before surgery in treating patients with thyroid cancer whose tumors have RET alterations (changes in the genetic material \[deoxyribonucleic acid (DNA)\]). Selpercatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving selpercatinib before surgery may help shrink the tumors and help control the disease.

Timeline

Start

2021-02-26

Primary completion

2027-11-30

Completion

2027-11-30

Drugs

Indications